Annovis Bio, Inc.
ANVSHealthcare|Biotechnology|US
$0.84
+0.18 (+26.31%)
DCF Value
$0.84
Cash / Share
$0.50
Financials
Financial Snapshot
Market Cap
$36.1M
Enterprise Value
$17.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$49.5M
Cash & Investments
$18.7M
Net Cash
$18.7M
Free Cash Flow (TTM)
-$43.3M
Operating CF (TTM)
-$43.3M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$18.7M
Quarterly Burn
$10.8M
Monthly Burn
$3.6M
Est. Runway
~1.7 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $347.5K | $35.3K | $1.9K | $8.1M | $45.7M | $28.4M | $5.8M | $10.6M | $19.5M | $18.7M | |
| Operating Cash Flow | -$537.5K | -$558.6K | -$476.5K | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M | -$43.3M | |
| Free Cash Flow | -$537.5K | -$558.6K | -$476.5K | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M | -$43.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $3.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$5.00 | |
| Financing Cash Flow | $332.5K | $246.4K | $443.1K | $12.0M | $46.7M | $4.6K | $17.3M | $26.7M | $34.6M | $44.9M |
R&D Spending
R&D (TTM)
$28.74B
R&D Intensity
—
R&D Growth vs Prior
+113887.8%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $273.4K | $111.6K | $776.3K | $3.1M | $8.5M | $16.5M | $38.8M | $20.0M | $25.2M | $28.74B | |
| SG&A | $409.1K | $602.3K | $829.4K | $3.6M | $6.1M | $9.0M | $6.2M | $6.7M | $4.5M | $3.66B |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $273.4K | $111.6K | $776.3K | $3.1M | $8.5M | $16.5M | $38.8M | $20.0M | $25.2M | $28.74B | |
| SG&A | $409.1K | $602.3K | $829.4K | $3.6M | $6.1M | $9.0M | $6.2M | $6.7M | $4.5M | $3.66B | |
| Operating Income | -$682.0K | -$714.0K | -$1.6M | -$6.6M | -$14.5M | -$25.5M | -$45.0M | -$26.7M | -$29.7M | -$49.5M | |
| Interest Expense | $84.00 | $66.00 | $0.00 | $47.2M | $0.00 | $0.00 | $0.00 | $1.9M | $0.00 | $1.6M | |
| Pretax Income | -$682.0K | -$714.0K | -$991.0K | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M | -$49.5M | |
| Net Income | -$682.0K | -$714.0K | -$991.0K | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M | -$49.5M | |
| EPS (Diluted) | -0.10 | -0.10 | -0.14 | -0.87 | -1.90 | -3.10 | -6.23 | -2.31 | -1.40 | -1.79 | |
| EBITDA | $433.00 | -$63.00 | -$378.00 | $0.00 | -$14.5M | -$25.3M | -$56.2M | -$22.7M | -$28.9M | -$49.1M | |
| Shares Out. (M) | 6.82 | 6.82 | 6.85 | 6.31 | 7.63 | 8.16 | 9.02 | 12.24 | 20.55 | 37.52 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $347.5K | $35.3K | $1.9K | $8.1M | $45.7M | $28.4M | $5.8M | $10.6M | $19.5M | $18.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $358.0K | $51.0K | $747.5K | $8.1M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M | $18.7M | |
| Total Assets | $358.0K | $51.0K | $1.1M | $8.1M | $46.0M | $36.0M | $10.2M | $13.9M | $21.1M | $22.0M | |
| Total Current Liabilities | $490.2K | $567.9K | $2.0M | $578.4K | $1.5M | $7.7M | $4.3M | $3.9M | $3.6M | $6.4M | |
| Long-Term Debt | $0.00 | $0.00 | $499.8K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $7.3M | $7.6M | $9.7M | $578.4K | $1.5M | $7.7M | $18.0M | $4.6M | $4.2M | $26.3M | |
| Stockholders' Equity | -$7.0M | -$7.6M | -$8.6M | $7.5M | $44.5M | $28.3M | -$7.8M | $9.3M | $16.9M | -$4.3M | |
| Retained Earnings | -$7.1M | -$7.8M | -$8.8M | -$14.2M | -$28.7M | -$54.1M | -$110.3M | -$134.8M | -$163.7M | -$196.1M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$537.5K | -$558.6K | -$476.5K | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M | -$43.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $3.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$5.00 | |
| Free Cash Flow | -$537.5K | -$558.6K | -$476.5K | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M | -$43.3M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $332.5K | $246.4K | $443.1K | $12.0M | $46.7M | $4.6K | $17.3M | $26.7M | $34.6M | $44.9M | |
| Issuance of Stock | $8.5K | $2.8K | -$78.6K | $9.2K | $46.6M | $4.6K | $16.9M | $26.7M | $34.6M | $44.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $530.0K | $12.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $48.5K | $82.7K | $8.5K | $1.9M | $4.7M | $9.2M | $4.6M | $3.8M | $1.8M | $984.0K | |
| Net Change in Cash | -$205.0K | -$312.2K | -$33.5K | $8.1M | $37.6M | -$17.3M | -$22.6M | $4.8M | $9.0M | $1.6M |
Dilution Tracker
Shares outstanding grew 225.8% over 5 years — significant dilution
Shares Outstanding
43M
5-Year Share Growth
+225.8%
Stock Issuance (TTM)
$44.9M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 6.82 | 6.82 | 6.85 | 6.31 | 7.63 | 8.16 | 9.02 | 12.24 | 20.55 | 37.52 | |
| Change vs Prior % | — | 0.0% | 0.4% | -7.8% | 20.9% | 7.0% | 10.5% | 35.6% | 68.0% | 82.6% | |
| Stock Issuance | $8.5K | $2.8K | -$78.6K | $9.2K | $46.6M | $4.6K | $16.9M | $26.7M | $34.6M | $44.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $48.5K | $82.7K | $8.5K | $1.9M | $4.7M | $9.2M | $4.6M | $3.8M | $1.8M | $984.0K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 9.8% | 9.4% | 11.6% | -72.4% | -32.6% | -89.4% | 725.1% | -264.2% | -171.2% | -686.0% | |
| ROA % | -190.5% | -1400.2% | -88.7% | -67.3% | -31.5% | -70.3% | -550.6% | -176.6% | -136.9% | -224.7% | |
| ROIC % | 515.7% | 138.1% | 179.7% | -88.1% | -32.7% | -90.1% | -759.6% | -265.8% | -170.2% | -400.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -4.7% | -124.9% | -313.5% | -118.9% | -75.5% | -76.5% | 40.7% | -11.2% | |
| Net Income | 0.0% | -4.7% | -38.8% | -451.2% | -165.2% | -74.8% | -121.9% | 56.2% | -17.3% | |
| EPS (Diluted) | 0.0% | 0.0% | -40.0% | -521.4% | -118.4% | -63.2% | -101.0% | 62.9% | 39.4% | |
| Operating Cash Flow | 0.0% | -3.9% | 14.7% | -733.3% | -130.0% | -89.6% | -130.9% | 45.2% | -17.0% | |
| Free Cash Flow | 0.0% | -3.9% | 14.7% | -733.3% | -130.0% | -89.6% | -130.9% | 45.2% | -17.0% | |
| R&D Expense | 0.0% | -59.2% | 595.5% | 293.4% | 177.6% | 94.8% | 134.9% | -48.5% | 26.1% | |
| SG&A Expense | 0.0% | 47.2% | 37.7% | 332.4% | 68.9% | 48.5% | -30.6% | 7.3% | -33.1% | |
| Total Assets | 0.0% | -85.8% | 2090.7% | 626.8% | 466.6% | -21.7% | -71.7% | 36.4% | 51.4% | |
| Book Value / Share | 0.0% | -9.0% | -12.5% | 195.4% | 388.1% | -40.5% | -124.8% | 188.9% | 7.3% | |
| Debt | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.4% | -7.8% | 20.9% | 7.0% | 10.5% | 35.6% | 68.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-7.45
10Y Low / Med / High3.01 / 4.22 / 6.58
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.84
Cash / Share
$0.50
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -95.90 | -95.90 | -68.50 | -8.67 | -9.25 | -4.33 | -3.00 | -2.49 | -2.47 | -0.47 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -9.39 | -8.61 | -7.65 | 6.31 | 3.01 | 3.87 | -21.77 | 6.58 | 4.22 | -7.45 | |
| EV/EBITDA | 150205.10 | -1037316.94 | -174989.16 | 0.00 | -6.10 | -3.21 | -2.90 | -2.23 | -1.79 | -0.35 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-18.31
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $10.9M | $16.7M | $50.5M |
| Net Income | -$28.9M | -$19.9M | -$31.1M |
| EPS | $-1.41 | $-0.97 | $-1.51 |
| # Analysts (EPS) | 2 | 2 | 2 |